BIOSTEM TECHNOLOGIES NEW - BSEM STOCK NEWS

BioStem Technologies Inc. has announced the approval of an IRB-sanctioned clinical study to investigate the utilization and effects of Vendaje in diabetic patients with foot ulcers. This study aims to enhance scientific understanding and improve care for people at risk of amputation. Diabetic foot ulcers are a significant risk, with approximately 15% of people with diabetes developing them. Vendaje is a placental-derived tissue allograft that provides mechanical protection and functional support for cell attachment, aiding the body's natural healing cascade.

BioStem Technologies Inc. partners with Venture Medical for the nationwide release of AmnioWrap2, a versatile biologic skin substitute for wound care.

BioStem Technologies Inc. engages PCG Advisory as advisor for investor relations and strategic communications.

NovaBay Pharmaceuticals launches Avenova Allograft in the US eyecare market, expected to compete in the $403.6 million ophthalmology amniotic membrane market. The product launch follows a previously announced agreement with BioStem Technologies. NovaBay's physician-dispensed channel continues to grow, providing a strong platform for the innovative product. Avenova Allograft is available in multiple sizes and aims to improve ocular surface health. NovaBay also offers a suite of other eyecare products.

NovaBay Pharmaceuticals and BioStem Technologies announce agreement for commercialization of Amniotic Tissue Allograft

Lovell Government Services and BioStem Technologies successfully list BioStem on key government contract vehicles, expanding their reach in federal healthcare systems.

BioStem Technologies (OTCQB: BSEM) commends a recent report by the U.S. Department of Health and Human Services Office of Inspector General, highlighting the failure of the Centers for Medicare and Medicaid Services (CMS) to ensure accurate Average Sales Price (ASP) reporting for skin substitute products. The report reveals compliance issues that could affect payment accuracy. CEO Jason Matuszewski emphasizes the importance of accurate ASP reporting for patient access to effective treatments and fair reimbursement for providers. BioStem is committed to regulatory compliance and has implemented measures to ensure transparency in reporting.

BioStem Technologies Inc. (OTCQB: BSEM) announced its acquisition of the majority assets from Auxocell Laboratories, Inc., a leading manufacturer in solid tissue processing equipment. This acquisition includes all assets excluding the AUX003 patent family, which will be licensed to BioStem. The deal encompasses 45 patents and 11 trademarks related to human placental tissue applications. The acquisition aims to enhance BioStem's intellectual property portfolio and manufacturing capabilities while accelerating growth in regenerative medicine. CEO Jason Matuszewski emphasized the strategic value of Auxocell's technology in producing regenerative products without enzymatic digestion.

BioStem Technologies Inc. (OTCQB: BSEM) announced on February 14, 2023, a Share Exchange Agreement with M.W. Jens Realty Investments, LLC to acquire 10% of the issued shares of its subsidiary, Blue Tech Industries, Inc. The agreement comes after a four-year partnership aimed at developing BioStem's tissue allograft division. In exchange for the shares, BioStem will issue 500,000 new shares of its common stock. CEO Jason Matuszewski expressed commitment to the company’s direction through this agreement, highlighting its focus on regenerative therapies and innovative manufacturing processes.